As of Feb 20
| +0.84 / +0.62%|
The 4 analysts offering 12-month price forecasts for Madrigal Pharmaceuticals Inc have a median target of 153.00, with a high estimate of 170.00 and a low estimate of 140.00. The median estimate represents a +12.54% increase from the last price of 135.95.
The current consensus among 4 polled investment analysts is to Buy stock in Madrigal Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.